Citations

Clear

1011 citation(s) found for "Barry, WT".

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction
Shah, Sanjiv J. , Kitzman, Dalane W. , Borlaug, Barry A. , Heerebeek, Loek van , Zile, Michael R. , Paulus, Walter J. , van Heerebeek, Loek, Kass, David A. , Shah, Sanjiv J , Borlaug, Barry A , Zile, Michael R

Mayo Clinic

Circulation | June 29, 2016 | Volume: 134 | Issue: 1 | Pages: 73-90

10.1161/circulationaha.116.021884 | PMID 27358439 Get It

Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for 50% of HF cases, and its prevalence relative to HF with reduced EF continues to rise. In contrast to HF with reduced EF, large trials testing neurohumoral inhibition in HFpEF failed to reach a positive outcome. This failure was recently attributed to distinct systemic and myocardial signaling in HFpEF and to diversity of HFpEF phenotypes. In this review, an HFpEF treatment strategy is proposed that addresses HFpEF-specific signaling and phenotypic diversity. In HFpEF, extracardiac comorbidities such as metabolic risk, arterial hypertension, and renal insufficiency drive left ventricular remodeling and dysfunction through systemic inflammation and coronary microvascular endothelial dysfunction. The latter affects left ventricular diastolic dysfunction through macrophage infiltration, resulting in interstitial fibrosis, and through altered paracrine signaling to cardiomyocytes, which become hypertrophied and stiff because of low nitric oxide and cyclic guanosine monophosphate. Systemic inflammation also affects other organs such as lungs, skeletal muscle, and kidneys, leading, respectively, to pulmonary hypertension, muscle weakness, and sodium retention. Individual steps of these signaling cascades can be targeted by specific interventions: metabolic risk by caloric restriction, systemic inflammation by statins, pulmonary hypertension by phosphodiesterase 5 inhibitors, muscle weakness by exercise training, sodium retention by diuretics and monitoring devices, myocardial nitric oxide bioavailability by inorganic nitrate-nitrite, myocardial cyclic guanosine monophosphate content by neprilysin or phosphodiesterase 9 inhibition, and myocardial fibrosis by spironolactone. Because of phenotypic diversity in HFpEF, personalized therapeutic strategies are proposed, which are configured in a matrix with HFpEF presentations in the abscissa and HFpEF predispositions in the ordinate.
Getting at the Heart of Central Obesity and the Metabolic Syndrome
Borlaug, Barry A. , Reddy, Yogesh N.V. , Nishimura, Rick , Borlaug, Barry A

Mayo Clinic

Circulation: Cardiovascular Imaging | June 16, 2016 | Volume: 9 | Issue: 6 | Pages: No page available

10.1161/circimaging.116.005110 | PMID 27307555 Get It

Abstract P1-10-18: Contraception use in young women with breast cancer
Rosenberg, SM, Dutton, CR, Ligibel, Jennifer A. , Barry, W, Ruddy, KJ, Sprunck-Harrild, K, Emmons, KM, Partridge, AH, Barry, W, Sprunck-Harrild, K

Mayo Clinic

Cancer Research | May 20, 2016 | Volume: 76 | Issue: 4_Supplement | Pages: P1-10-18-P1-10-18

10.1158/1538-7445.sabcs15-p1-10-18 Get It

Abstract Background: Young women with breast cancer need highly effective contraception given the potential implications of unplanned pregnancy for optimal treatment, and the teratogenic risks. We sought to determine the contraceptive methods used by young women after diagnosis (dx) of breast cancer and factors associated with use of less effective methods or no contraceptive method, which confers a 6-90% annual risk of pregnancy in sexually active women in contrast to highly effective methods (risk <1%). Methods: As part of a randomized trial conducted in 54 sites to test an education and support intervention for young women with breast cancer and their oncologists, we surveyed women about their pre-dx, current, and planned contraceptive use, and about communication with their providers regarding contraception. Women enrolled within 3 months of dx; contraception items were included on 3- and 12-month post-enrollment surveys. Intrauterine device (IUD) use, tubal sterilization, hysterectomy or bilateral salpingo-oophorectomy (hyst/BSO) after dx, or male partner vasectomy were classified as highly effective methods; all other methods and non-use were categorized as less effective. We excluded women not at risk of pregnancy: hyst/BSO prior to dx, or no indication for contraception. We used logistic regression to explore factors associated with use of less effective methods. Results: Of 424 women who completed the 3-month post-enrollment survey, median age at dx was 39 (range 22-45). 312 women at risk of pregnancy were included in this analysis, including 291 reporting sexual activity with a male partner within the last 6 months, and 21 reporting no recent sexual activity but reporting use of birth control. 123 women (39%) used highly effective contraceptive methods prior to dx; after dx, 161 (52%) reported current use of or a plan to use a highly effective method. 19 women (6%) reported use of a hormonal birth control method since dx; 7 (2%) reported withdrawal as their only contraceptive method; 25 (8%) reported no contraception. 30% of women did not recall a discussion of avoiding pregnancy or need for contraception during treatment with their providers. In multivariable analyses (N=310), desire for additional biologic children (OR 7.54, 95% CI 3.88-14.66) and provider discussion of contraception and pregnancy (OR 2.13 95% CI 1.20-3.78) were associated with use of less effective contraception. Age, race/ethnicity, disease stage, and partner status were not significantly associated with use of less effective methods. Conclusion: About half of women who are at risk of pregnancy reported use or planned use of less effective contraceptive methods or no method of contraception following dx of breast cancer. Women with breast cancer and their providers may benefit from targeted education on contraceptive options and method effectiveness. Citation Format: Rosenberg SM, Dutton CR, Ligibel J, Barry W, Ruddy KJ, Sprunck-Harrild K, Emmons KM, Partridge AH. Contraception use in young women with breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-10-18.
Impaired Right Ventricular–Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction
Hussain, Imad , Mohammed, Selma F. , Forfia, Paul R. , Borlaug, Barry A. , Gallup, Dianne , Redfield, Margaret M. , Gallup, Dianne S, Lewis, Gregory D. , Borlaug, Barry A

Mayo Clinic

Circulation: Heart Failure | April 12, 2016 | Volume: 9 | Issue: 4 | Pages: No page available

10.1161/circheartfailure.115.002729 | PMID 27072860 Get It

Background— Right ventricular (RV) dysfunction (RVD) is a poor prognostic factor in heart failure with preserved ejection fraction (HFpEF). The physiological perturbations associated with RVD or RV function indexed to load (RV–pulmonary arterial [PA] coupling) in HFpEF have not been defined. HFpEF patients with marked impairment in RV–PA coupling may be uniquely sensitive to sildenafil. Methods and Results— In a subset of HFpEF patients enrolled in the Phosphodiesteas-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) trial, physiological variables and therapeutic effect of sildenafil were examined relative to the severity of RVD (tricuspid annular plane systolic excursion [TAPSE]) and according to impairment in RV–PA coupling (TAPSE/pulmonary artery systolic pressure) ratio. The prevalence of atrial fibrillation and diuretic use, n-terminal probrain natriuretic peptide levels, renal dysfunction, neurohumoral activation, myocardial necrosis and fibrosis biomarkers, and the severity of diastolic dysfunction all increased with severity of RVD. Peak oxygen consumption decreased and ventilatory inefficiency (VE/VCO 2 slope) increased with increasing severity of RVD. Many but not all physiological derangements were more closely associated with the TAPSE/pulmonary artery systolic pressure ratio. Compared with placebo, at 24 weeks, TAPSE decreased, and peak oxygen consumption and VE/CO 2 slope were unchanged with sildenafil. There was no interaction between RV–PA coupling and treatment effect, and sildenafil did not improve TAPSE, peak oxygen consumption, or VE/VCO 2 in patients with pulmonary hypertension and RVD. Conclusions— HFpEF patients with RVD and impaired RV–PA coupling have more advanced heart failure. In RELAX patients with RVD and impaired RV–PA coupling, sildenafil did not improve RV function, exercise capacity, or ventilatory efficiency. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00763867.
Cardiac Aging and the Fountain of Youth
Borlaug, Barry A. , Borlaug, Barry A

Mayo Clinic

European Journal of Heart Failure | April 12, 2016 | Volume: 18 | Issue: 6 | Pages: 611-612

10.1002/ejhf.525 | PMID 27072490 Get It

Intranasal Vaccination Affords Localization and Persistence of Antigen-Specific CD8+ T Lymphocytes in the Female Reproductive Tract
Singh, Shailbala , Schluns, Kimberly S. , Yang, Guojun , Anthony, Scott M. , Barry, Michael A. , Sastry, K. Jagannadha , Barry, Michael A

Mayo Clinic

Vaccines | March 17, 2016 | Volume: 4 | Issue: 1 | Pages: 7

10.3390/vaccines4010007 | PMID 26999228 Get It

Immunization strategies generating large numbers of antigen-specific T cells in the female reproductive tract (FRT) can provide barrier protection against sexually-transmitted pathogens, such as the human immunodeficiency virus (HIV) and human papillomaviruses (HPV). The kinetics and mechanisms of regulation of vaccine-induced adaptive T cell-mediated immune responses in FRT are less well defined. We present here evidence for intranasal delivery of the model antigen ovalbumin (OVA) along with alpha-galactosylceramide adjuvant as a protein vaccine to induce significantly higher levels of antigen-specific effector and memory CD8+ T cells in the FRT, relative to other systemic and mucosal tissues. Antibody blocking of the CXCR3 receptor significantly reduced antigen-specific CD8+ T cells subsequent to intranasal delivery of the protein vaccine suggesting an important role for the CXCR3 chemokine-receptor signaling for T cell trafficking. Further, intranasal vaccination with an adenoviral vector expressing OVA or HIV-1 envelope was as effective as intramuscular vaccination for generating OVA- or ENV-specific immunity in the FRT. These results support the application of the needle-free intranasal route as a practical approach to delivering protein as well as DNA/virus vector-based vaccines for efficient induction of effector and memory T cell immunity in the FRT.
A new model of an arteriovenous fistula in chronic kidney disease in the mouse: beneficial effects of upregulated heme oxygenase-1
Lu, Kang , Grande, Joseph P. , Hillestad, Matthew L. , Croatt, Anthony J., Barry, Michael A. , Katušić, Zvonimir S. , Nath, Karl A. , Kang, Lu, Barry, Michael A

Mayo Clinic

American Journal of Physiology-Renal Physiology | December 16, 2015 | Volume: 310 | Issue: 6 | Pages: F466-F476

10.1152/ajprenal.00288.2015 | PMID 26672617 Get It

The arteriovenous fistula (AVF) is the preferred hemodialysis vascular access, but it is complicated by high failure rates and attendant morbidity. This study provides the first description of a murine AVF model that recapitulates two salient features of hemodialysis AVFs, namely, anastomosis of end-vein to side-artery to create the AVF and the presence of chronic kidney disease (CKD). CKD reduced AVF blood flow, observed as early as 3 days after AVF creation, and increased neointimal hyperplasia, venous wall thickness, thrombus formation, and vasculopathic gene expression in the AVF. These adverse effects of CKD could not be ascribed to preexisting alterations in blood pressure or vascular reactivity in this CKD model. In addition to vasculopathic genes, CKD induced potentially vasoprotective genes in the AVF such as heme oxygenase-1 (HO-1) and HO-2. To determine whether prior HO-1 upregulation may protect in this model, we upregulated HO-1 by adeno-associated viral gene delivery, achieving marked venous induction of the HO-1 protein and HO activity. Such HO-1 upregulation improved AVF blood flow and decreased venous wall thickness in the AVF. Finally, we demonstrate that the administration of carbon monoxide, a product of HO, acutely increased AVF blood flow. This study thus demonstrates: 1) the feasibility of a clinically relevant murine AVF model created in the presence of CKD and involving an end-vein to side-artery anastomosis; 2) the exacerbatory effect of CKD on clinically relevant features of this model; and 3) the beneficial effects in this model conferred by HO-1 upregulation by adeno-associated viral gene delivery.
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Diamond, Eli L. , Durham, Benjamin H. , Haroche, Julien , Yao, Zhan , Ma, Jing , Wang, Zhaoming , Choi, John , Kim, Eun Hee , Cohen‐Aubart, Fleur , Lee, Stanley Chun-Wei , Gao, Yijun , Micol, Jean‐Baptiste , Campbell, Patrick , Walsh, Michael P. , Sylvester, Brooke E., Dolgalev, Igor , Aminova, Olga, Heguy, Adriana , Zappile, Paul, Nakitandwe, Joy , Ganzel, Chezi , Dalton, James , Ellison, David W. , Estrada‐Veras, Juvianee , Lacouture, Mario E. , Gahl, William A. , Stephens, Philip J., Miller, Vincent A. , Ali, Siraj M. , Briggs, Samuel, Fasan, Omotayo , Block, Jared , Héritier, Sébastien , Solit, David B. , Hyman, David M. , Baselga, José , Jankú, Filip , Taylor, Barry S. , Amoura, Zahir , Rosen, Neal , Parikh, Sameer A. , Ross, Jeffrey S , Donadieu, Jean , Park, Christopher Y. , Doǧan, Ahmet , Emile, Jean‐François , Gruber, Tanja Andrea , Abdel‐Wahab, Omar , Diamond, Eli L , Wang, Zhaoming , Héritier, Sébastien , Durham, Benjamin

Mayo Clinic

Cancer Discovery | November 13, 2015 | Volume: 6 | Issue: 2 | Pages: 154-165

10.1158/2159-8290.cd-15-0913 | PMID 26566875 Get It

Abstract Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans cell histiocytosis (LCH) and non-Langerhans cell histiocytosis (non-LCH), respectively. The discovery of BRAFV600E mutations in approximately 50% of these patients provided the first molecular therapeutic target in histiocytosis. However, recurrent driving mutations in the majority of patients with BRAFV600E–wild-type non-LCH are unknown, and recurrent cooperating mutations in non-MAP kinase pathways are undefined for the histiocytic neoplasms. Through combined whole-exome and transcriptome sequencing, we identified recurrent kinase fusions involving BRAF, ALK, and NTRK1, as well as recurrent, activating MAP2K1 and ARAF mutations in patients with BRAFV600E–wild-type non-LCH. In addition to MAP kinase pathway lesions, recurrently altered genes involving diverse cellular pathways were identified. Treatment of patients with MAP2K1- and ARAF-mutated non-LCH using MEK and RAF inhibitors, respectively, resulted in clinical efficacy, demonstrating the importance of detecting and targeting diverse kinase alterations in these disorders. Significance: We provide the first description of kinase fusions in systemic histiocytic neoplasms and activating ARAF and MAP2K1 mutations in non-Langerhans histiocytic neoplasms. Refractory patients with MAP2K1- and ARAF-mutant histiocytoses had clinical responses to MEK inhibition and sorafenib, respectively, highlighting the importance of comprehensive genomic analysis of these disorders. Cancer Discov; 6(2); 154–65. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 109
Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease
Palmer, Jeanne , Chai, Xiaoyu , Pidala, Joseph, Inamoto, Yoshihiro , Storer, Barry E. , Pusic, Iskra , Arora, Mukta , Pavletic, Steven Z. , Lee, Stephanie J. , Martin, Paul J. , Flowers, Mary E.D. , Lee, Stephanie J

Mayo Clinic

Blood | November 2, 2015 | Volume: 127 | Issue: 1 | Pages: 160-166

10.1182/blood-2015-08-662874 | PMID 26527676 Get It

Key Points Survival of chronic GVHD patients was predicted by clinician-assessed response and changes in patient-reported outcomes. FFS was predicted by clinician-assessed response, changes in patient-reported outcomes, and the 2014 NIH response criteria.
Work Relative Value Units Generated by Pediatric Urologists
Kogan, Barry A., Ritchey, Michael L., Feustel, Paul J. , Ritchey, Michael, Feustel, Paul

Mayo Clinic

Urology Practice | October 25, 2015 | Volume: 3 | Issue: 1 | Pages: 1-6

10.1016/j.urpr.2015.05.010 | PMID 37592705 Get It